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Heparin and heparan sulfate (HS) are structurally di-
verse glycosaminoglycans (GAG) that are known to in-
teract, via unique structural motifs, with a wide range of
functionally distinct proteins and modulate their bio-
logical activity. To define the GAG motifs that interact
with proteins, we assessed the ability of 15 totally syn-
thetic HS mimetics to interact with 10 functionally di-
verse proteins that bind heparin/HS. The HS mimetics
consisted of cyclitol-based pseudo-sugars coupled by
linkers of variable chain length, flexibility, orientation,
and hydrophobicity, with variations in sulfation also
being introduced into some molecules. Three of the pro-
teins tested, namely hepatocyte growth factor, eotaxin,
and elastase, failed to interact with any of the sulfated
linked cyclitols. In contrast, each of the remaining seven
proteins tested exhibited a unique reactivity pattern
with the panel of HS mimetics, with tetrameric cyclitols
linked by different length alkyl chains being particu-
larly informative. Thus, compounds with short alkyl
spacers (2–3 carbon atoms) effectively blocked the inter-
action of fibroblast growth factor-1 (FGF-1) and lipopro-
tein lipase with heparin/HS, whereas longer chain spac-
ers (7–10 carbon atoms) were required for optimal
inhibition of FGF-2 and vascular endothelial growth fac-
tor binding. This effect was most pronounced with the
chemokine, interleukin-8, where alkyl-linked tetra-
meric cyclitols were essentially inactive unless a spacer
of >7 carbon atoms was used. The heparin-inhibitable
enzymes heparanase and cathepsin G also displayed
characteristic inhibition patterns, cathepsin G interact-
ing promiscuously withmost of the sulfated cyclitols but
heparanase activity being inhibited most effectively by
HS mimetics that structurally resemble a sulfated pen-
tasaccharide. These data indicate that a simple panel of
HS mimetics can be used to probe the HS binding spec-
ificity of proteins, with the position of anionic groups in
the HS mimetics being critical.
Heparan sulfate (HS)1 is a glycosaminoglycan that is ubiq-
uitously expressed as a proteoglycan on cell surfaces and
throughout the extracellular matrix (ECM) in most multicellu-
lar animals (1–5). The polysaccharide is composed of alternat-
ing glucuronic acid and N-acetylglucosamine units, which, dur-
ing biosynthesis, are subjected to a range of modifications such
as O-sulfation at various positions, N-deacetylation, and N-
sulfation of N-acetylglucosamine residues as well as C-5 epi-
merization of glucuronic acid to iduronic acid. Theoretically up
to 48 different disaccharides could occur in HS due to these
modifications, although so far only 23 have been identified (2).
Nevertheless, as a result of the presence of these different
disaccharides, HS chains exhibit remarkable structural heter-
ogeneity. Such diversity is further enhanced by the consider-
able variation in chain length of the glycosaminoglycan. Hep-
arin, a glycosaminoglycan with a much more restricted cellular
distribution than HS, is structurally closely related to HS but
has 80% of its disaccharide units epimerized or sulfated com-
pared with only 10% of disaccharides being modified in HS
(6). The modified disaccharides in HS, however, are concen-
trated in “hot spots” along the molecular backbone and sepa-
rated by flexible spacers of low sulfation, rather than being
evenly distributed throughout the polysaccharide chain (2, 3).
Both heparin and HS are known to interact with a wide
range of functionally diverse proteins, such as growth factors,
cytokines, chemokines, proteases, lipases, and cell adhesion
molecules (2–4, 6–8). Furthermore, there is increasing evi-
dence to suggest that these proteins bind to unique structural
motifs on the HS chains, with different tissues and cell types
controlling their ability to interact with various HS-binding
proteins by varying their repertoire of sugar sequences. In fact,
genetic studies in Drosophila and mice (3, 9–11) have demon-
strated unequivocally that a lack of specific HS modifications
can impair development, whereas mice deficient in HS die at
the gastrula stage (12). At the physiological level, it appears
that HS can regulate the function of HS-binding proteins in a
number of ways, with some well characterized examples being
listed below. First, depots of growth factors and cytokines can
exist in the ECM bound to HS (13, 14). These can be liberated
by ECM-degrading enzymes, such as heparanase, and be made
available for important physiological processes such as wound
healing and angiogenesis (15, 16). Second, cell surface HS can
interact with both HS-binding growth factors and growth factor
receptors and, thereby, greatly facilitate signal transduction
via such receptors (3, 11, 17, 18). Third, chemokines and cyto-
kines can form stable gradients within tissues by associating
with HS chains in the ECM, an interaction that aids leukocyte
entry into inflammatory sites (19). Finally, the activity of a
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range of enzymes can be modulated by heparin and HS, with
the classic example being the ability of heparin to potentiate
antithrombin III-mediated inhibition of thrombin (2, 6). Simi-
larly, heparin, and to a lesser extent HS, can both directly and
indirectly inhibit the proteolytic activity of neutrophil elastase
and cathepsin G (20–22).
Because data are emerging that suggest different HS-bind-
ing proteins tend to interact with unique structural motifs
within HS, the possibility now exists for the design and syn-
thesis of HS mimetics, which selectively block undesirable pro-
tein-HS interactions (23). In fact, we have recently developed
an HS-mimetic, called PI-88, that exhibits anti-angiogenic,
anti-metastatic, and anti-restenotic activities and that is cur-
rently undergoing Phase II clinical trials in cancer patients.
This drug, which is composed primarily of sulfated phospho-
mannopentaose and phosphomannotetraose oligosaccharide
units, is believed to exert its biological effects by blocking the
enzymatic activity of the ECM-degrading enzyme, heparanase,
and by interfering with the action of HS-binding growth factors
such as fibroblast growth factor-1 (FGF-1), FGF-2, and vascu-
lar endothelial growth factor (VEGF) (24–26). PI-88, however,
interferes with a relatively broad range of protein-HS interac-
tions, because it represents a modified natural product contain-
ing a mixture of differentially sulfated oligosaccharides. To
obtain homogeneous and structurally well defined HS mimet-
ics, a family of totally synthetic molecules, namely sulfated
linked cyclitols, was prepared. This study compares the ability
of 15 different sulfated linked cyclitols to interact with 10
functionally diverse proteins. It was found that each protein
examined exhibited a unique reactivity pattern with the panel
of sulfated cyclitols, confirming the view that many HS-binding
proteins preferentially bind to unique structural motifs in HS.
This study also highlights the selective therapeutic potential of
HS mimetics and demonstrates that a relatively simple panel
of mimetics can provide considerable information regarding the
HS binding specificity of proteins.
EXPERIMENTAL PROCEDURES
Reagents—PI-88, provided by Progen Industries Ltd. (Brisbane, Aus-
tralia), was prepared as described previously (24, 27) by the sulfation of
phosphomanno-oligosaccharides derived from the phosphomannan pro-
duced by the yeast Pichia holsti. It consists predominantly of sulfated
phosphomannopentaose and phosphomannotetraose with its compo-
nents having molecular masses in the range 1400 to 3100 Da.
Bovine lung heparin (mean molecular mass 12.5 kDa) was purchased
from Sigma-Aldrich. Porcine mucosal HS (ORG 553) was a generous gift
from Organon Int. Bv (Oss, The Netherlands). FGF-1, FGF-2, VEGF165,
interleukin-8 (IL-8), and eotaxin were supplied by R & D Systems,
Minneapolis, MA. Hepatocyte growth factor (HGF) was a generous gift
of Dr. Oyvind Hjertner, Institute of Cancer Research and Molecular
Biology, Medisinsk Teknisk Senter, Trondheim, Norway. Human plate-
let heparanase was purified according to the method of Freeman and
Parish (28). Bovine lipoprotein lipase (LpL), human leukocyte elastase,
and human leukocyte cathepsin G were purchased from Sigma-Aldrich.
Surface Plasmon Resonance—Binding studies were performed, as
previously reported (25), on a BIAcore 2000 surface plasmon resonance-
based biosensor (BIAcore, Uppsala, Sweden) using either biotinylated
bovine lung heparin or biotinylated porcine mucosal HS immobilized on
a CM5 sensor chip (BIAcore). Briefly, the carboxymethylated surface of
the sensor chip was first activated with a mixture of N-hydroxysuccin-
imide and N-ethyl-N-(3-diethylaminopropyl)carbodiimide, NeutrAvi-
din was then covalently attached to the chip surface, and any residual
activated ester groups were blocked by ethanolamine hydrochloride.
Biotinylated heparin or biotinylated HS was then bound to the immo-
bilized NeutrAvidin, with the flow cells finally being washed with 4 M
NaCl. The different heparin/HS-binding proteins (25–68 nM) were in-
jected into the flow cells of the biosensor, with binding and dissociation
each being monitored for 3–10 min. Data points were collected contin-
uously during the binding and dissociation phases, and analysis was
based on the response once saturation binding had been reached. Be-
tween each cycle, the sensor surface was regenerated with 4 M NaCl.
Simultaneous measurements were obtained from the four flow cells
with flow cells 1 and 3 containing NeutrAvidin alone (to establish
background binding), flow cell 2 containing immobilized biotinylated
heparin, and flow cell 4 containing immobilized biotinylated HS. Flow
cells 1 and 3 were used as blank reference cells, with the background
binding to NeutrAvidin in flow cell 1 and 3 being subtracted from the
responses in flow cells 2 and 4. The sensorgrams were analyzed with the
aid of the BIAevaluation software version 3.0.2 (BIAcore). Baselines
were adjusted to zero for all curves and background sensorgrams sub-
tracted from experimental sensorgrams to produce curves of specific
binding.
Enzyme Assays—Heparanase activity was assayed as described pre-
viously (29). Cathepsin G activity was determined in 96-well U-bot-
tomed plastic microplates by incubating human leukocyte cathepsin G
(40 l/well, 100 ng/well of enzyme), in the presence or absence of
inhibitors, with the fluorogenic substrate N-succinyl-Ala-Ala-Pro-Phe-
amidomethylcoumarin (Sigma-Aldrich) in 50 mM sodium acetate buffer,
FIG. 1. Structures of the various sulfated linked cyclitols used
in this study. All compounds shown are related to 1, with the excep-
tions being 6a and 10a that are compound 1a derivatives.
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pH 6.6, containing 50 mM NaCl and 0.1% (v:v) Brij 35. The mixture was
incubated at 37 °C for 60 min, the reaction was stopped by the addition
of 40 l/well of 250 mM acetic acid, and fluorescence was determined
using a Cytofluor II fluorescence plate reader (PerSeptive Biosystems,
Framingham, MA) employing an excitation wavelength of 360 nm and
an emission wavelength of 460 nm. Because plastic microplates inhib-
ited elastase enzymic activity, elastase assays were performed in 0.5-ml
polycarbonate tubes with reaction mixtures, upon reaction completion,
being transferred to 96-well plastic microplates for reading by the
fluorescence plate reader. Human leukocyte elastase (40 l/tube, 20
ng/tube of enzyme) was incubated, in the presence or absence of inhib-
itors, with the fluorogenic substrate MeOSuc-Ala-Ala-Pro-Val-amido-
methylcoumarin (ICN Biomedicals, Irvine, CA) in 50 mM Tris-HCl
buffer, pH 7.5, containing 50 mM NaCl and 0.1% (v:v) Brij 35. The
mixture was incubated at 37 °C for 20 min, the reaction was then
stopped by the addition of 40 l/well of 250 mM acetic acid, and the
mixture was transferred to a 96-well microplate, with fluorescence
being determined as for cathepsin G.
RESULTS
Synthesis and Structural Properties of HS Mimetics—A se-
ries of HS mimetics was synthesized, these being composed of
cyclitol subunits, which represent pseudo-sugars in which the
pyranosyl-ring oxygen has been replaced by a methylene unit.
Such compounds are highly stable and “immune ” from glyco-
sidic cleavage. The synthesis and physicochemical properties of
these compounds will be described in detail elsewhere.2 Briefly,
the synthesis involved the biotransformation of iodobenzene
using the genetically engineered microorganism Escherichia
coli JM109 (pDTG601), which overexpresses toluene dioxygen-
ase, to yield the corresponding iodinated cis-1,2-dihydrocat-
echol as starting material (30, 31). A suitably protected epoxy
derivative of this starting material was then reacted with the
relevant 1,-diaminoalkane or -arene to give, after appropriate
deprotection and de-iodination, the polyhydroxylated precursor
to compounds of the general type 1 (Fig. 1). cis-Dihydroxylation
of the double bond within the tetrameric cyclitols formed as
2 M. G. Banwell, A. J. Edwards, V. Ferro, C. Freeman, L. Liu, and
C. R. Parish, manuscript in preparation.
FIG. 2. Ability of a range of sulfated linked cyclitols to inhibit the binding of FGF-1, FGF-2, and VEGF to immobilized heparin. Data
obtained using an optical biosensor and presented as percentage inhibition of growth factor binding relative to control binding in the absence of an
inhibitor. In each case equimolar concentrations of growth factor and inhibitor were used, i.e. 25 nM for FGF-1, 34 nM for FGF-2, and 25 nM for VEGF.
The heparan sulfate mimetic, PI-88, was included as a positive control. Inhibitory activity of the alkyl-linked cyclitols is depicted in panels A–C, and
that of other linked cyclitols is depicted in panel D. Data values are the mean of at least two to three determinations with a variation of 5%.
TABLE I
General properties of heparin/HS-interacting proteins
used in this study
Protein class Protein
IC50
a
Heparinb PI-88c
nM
Heparin/HS binding FGF-1 5 10
growth factors FGF-2 5 34
VEGF 20 25
HGF 5 30
Heparin/HS binding IL-8 8 2000
chemokines Eotaxin 25 2000
Heparin/HS binding LpL 2 30
enzymes
Heparin inhibitable Heparanase 160 1260
enzymes Cathepsin G 25 140
Elastase 2 5000
a Concentration of heparin or PI-88 required to inhibit protein bind-
ing or enzymic activity by 50%. With heparin/HS-binding proteins hep-
arin and PI-88 were assessed for their ability to inhibit the binding of 25
nM FGF-1, 34 nM FGF-2, 25 nM VEGF, 20 nM HGF, 68 nM IL-8, 25 nM
eotaxin, or 50 nM LpL to immobilized heparin using an optical biosen-
sor. Enzyme assays were performed as described under “Experimental
Procedures.”
b Bovine lung heparin (12.5 kDa).
c Phosphomannopentaose sulfate.
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just described gave, after deprotection, the precursors to com-
pounds of the form 1a (Fig. 1). Exhaustive sulfation of each
member of these two series of polyhydroxylated tetramers with
pyridine-SO3 followed by work up with sodium bicarbonate
then afforded the target compounds 1 or 1a, which represent
two families of related compounds (Fig. 1). In one family, each
pseudo-sugar unit contains three sulfation sites (1, Fig. 1),
whereas with the other family five sulfation sites were incor-
porated within each unit (1a, Fig. 1). A less sulfated penta-
meric cyclitol was also generated by employing a triamino-
linker (14, Fig. 1). In the case of the sulfated tetrameric
cyclitols a range of linkers was used, namely alkyl chain linkers
varying in length from 2 to 10 carbon atoms (2–10, 6a, and 10a,
Fig. 1), p-xylyl and m-xylyl linkers (11 and 12, Fig. 1), and a
sulfated propylene linker (13, Fig. 1). Compounds 6a and 10a
represent more highly sulfated tetrameric cyclitols (1a) linked
by 6-carbon and 10-carbon alkyl chains, respectively. Thus, a
total of 15 cyclitol-based HS mimetics were employed in this
study, the key structural features of these compounds being the
presence of highly sulfated regions separated by spacers of
variable length, flexibility, orientation, and hydrophobicity.
Ability of Heparin and PI-88 to Interact with Several Hepa-
rin/HS Binding Proteins—The binding properties of 10 hepa-
rin/HS-interacting proteins were investigated in this study
(Table I). The proteins examined consisted of four heparin/HS
binding growth factors (FGF-1, FGF-2, VEGF165, and HGF),
two chemokines (IL-8 and eotaxin), one HS-binding enzyme
(LpL), and three heparin-inhibitable enzymes (heparanase, ca-
thepsin G, and elastase). The ability of the different HS mimet-
ics to inhibit the binding of the growth factors, chemokines, and
LpL to heparin/HS was quantified using an optical biosensor
with the biosensor chips carrying immobilized heparin or HS.
In each case concentrations of the binding proteins were used,
which exhibited 60–90% maximal binding as detected by the
biosensor. In the case of the heparin-inhibitable enzymes
standard enzyme assays were established for each enzyme, and
the ability of the different compounds to inhibit enzymatic
activity was quantified.
In initial studies bovine lung heparin and the sulfated oligo-
saccharide, PI-88, were assessed for their inhibitory activity
with IC50 values being presented in Table I. The biosensor data
presented in Table I are those obtained using immobilized
heparin, but comparable results were observed when immobi-
lized HS was used, although due to there usually being fewer
protein binding sites on HS (relative to heparin) the sensor-
gram response was considerably lower with immobilized HS.
The one exception to this rule was eotaxin, which interacted
strongly with immobilized heparin but failed to bind to immo-
bilized HS. PI-88 exhibited substantial inhibitory activity
against seven of the heparin/HS-interacting proteins tested,
namely FGF-1, FGF-2, VEGF165, HGF, LpL, heparanase, and
cathepsin G. On the other hand, PI-88 was essentially inactive
against the two chemokines (IL-8 and eotaxin) and elastase.
Of the seven heparin/HS-binding proteins whose activity
was blocked by PI-88, heparin was usually a more effective
inhibitor than PI-88. Thus, in terms of IC50, PI-88 was 2
(FGF-1)-, 7 (FGF-2)-, 6 (HGF)-, 15 (LpL)-, 8 (heparanase)-, and
6 (cathepsin G)-fold less active than heparin (Table I). The one
exception was VEGF165 where PI-88 and heparin were equally
effective. These differences are probably due to heparin being a
polydisperse linear polysaccharide with a mean molecular
mass of 12.5 kDa and, therefore, potentially having multiple
protein binding sites, whereas the much smaller PI-88 (1.4–
3.1 kDa) can probably only accommodate 1–2 heparin/HS-bind-
ing proteins per molecule. The fact that, in most cases, the IC50
for heparin was substantially lower than the protein concen-
tration used in the biosensor binding assays highlights this
point, with LpL being an extreme example, i.e. 50 nM LpL was
used in the binding assay but the heparin IC50 was only 2 nM.
Ability of Sulfated Cyclitols to Block Protein-HS Interactions
on the Optical Biosensor—The next series of experiments uti-
lized the optical biosensor to assess the ability of the 15 above-
mentioned sulfated cyclitols to inhibit the binding of the four
growth factors (FGF-1, FGF-2, VEGF165, and HGF), two che-
mokines (IL-8 and eotaxin), and LpL to immobilized heparin.
When appropriate the different compounds were compared
with PI-88 for their inhibitory activity. As with the data pre-
sented in Table I, comparable results were obtained with im-
mobilized heparin and HS, but only the heparin data is pre-
sented here.
In the case of FGF-1 and FGF-2 binding to immobilized
heparin, all 15 sulfated cyclitols exhibited some inhibitory ac-
tivity. However, a comparison of the percentage inhibition of
binding when equimolar concentrations of the inhibitor and
growth factor were used is very informative (Fig. 2). In the case
of the less sulfated tetrameric cyclitols containing alkyl chain
spacers (compounds 2–10), inhibition of FGF-1 binding was
most effective and approaching that of PI-88 with the shorter
(2–3 carbon atom) alkyl spacers, whereas the converse was true
with FGF-2, compounds with alkyl spacers 5 carbon atoms
being the most effective (Fig. 2, A and B). Interestingly, the
more highly sulfated alkyl chain-linked tetrameric cyclitols
(compounds 6a and 10a) were somewhat less effective at in-
hibiting FGF-2 binding than their less sulfated counterparts
(compounds 6 and 10). Alkyl chain length was even more crit-
ical in determining the inhibitory activity of the sulfated tet-
racyclitols for the VEGF165-heparin interaction (Fig. 2C). Com-
pound 2 was essentially inactive, with increasing alkyl chain
length from 3–7 carbon atoms steadily increasing inhibitory
FIG. 3. Ability of a range of sulfated linked cyclitols to inhibit
the binding of IL-8 and LpL to immobilized heparin. Data ob-
tained using an optical biosensor and presented as concentration (nano-
molar) of each inhibitor required to block binding of IL-8 (68 nM) (A) or
LpL (50 nM) (B) by 50% (IC50). The heparan sulfate mimetic, PI-88, is
included for comparison. Data values are the mean of at least two to
three determinations with a variation of 5%.
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activity to the level of PI-88. Also, unlike FGF-2, increasing the
extent of sulfation of the cyclitol units did not change inhibitory
activity, i.e. compare compounds 6a and 10a with 6 and 10.
Sulfated tetracyclitols containing a p-xylyl or m-xylyl linker
(compounds 11 and 12) or the sulfated pentameric cyclitol
(compound 14) were essentially as effective as PI-88 at blocking
FGF-1, FGF-2, and VEGF165 binding (Fig. 1D). However, com-
pound 13, a sulfated tetracyclitol linked by a sulfated propyl-
ene moiety, was unable to block VEGF165 binding despite being
quite an effective inhibitor of the interaction of FGF-1 and
FGF-2 with heparin/HS (Fig. 1D). Thus, incorporating a sulfate
group in the 3-carbon atom alkyl spacer did not result in
inhibitory activity against VEGF165, i.e. both compounds 3 and
13 had little or no VEGF-specific inhibitory activity. Finally,
unlike the other heparin/HS-binding growth factors, the
binding of HGF (20 nM) to immobilized heparin was not
significantly affected by any of the 15 sulfated cyclitols tested.
Thus, even when using sulfated cyclitol concentrations as high
as 0.5–1.0 M negligible inhibitory activity was observed
(data not shown), despite PI-88 having an IC50 for HGF of 30 nM
(Table I).
In contrast with FGF-1, FGF-2, and VEGF, a totally differ-
ent pattern of inhibition was obtained with the chemokines
eotaxin and IL-8. As discussed earlier, PI-88 was unable to
block the binding of both chemokines to immobilized heparin
(Table I), and all 15 sulfated cyclitols were also inactive against
eotaxin (data not shown). On the other hand, 4 of the 15
sulfated cyclitols did effectively block the IL-8-heparin interac-
tion, with the remaining 11 compounds being totally ineffectual
(Fig. 3A). Thus, alkyl-linked tetrameric cyclitols were inactive
unless a spacer of 7 carbon atoms was used, an extension of
the alkyl chain spacer from 7 to 8 carbon atoms resulting in at
least a 40-fold increase in inhibitory activity. In fact, compound
8 displayed an IC50 (50 nM) essentially equimolar with the IL-8
concentration (68 nM) used in the binding assay. Compounds 9
and 10 were also quite strong inhibitors, although not as effec-
tive as compound 8, with the more highly sulfated 10a giving
comparable inhibition to 10.
Yet another unique inhibition profile was obtained with LpL
(Fig. 3B). In this case compound 2 was the most active, a
lengthening of the alkyl chain spacer from 2 to 3 carbon atoms
resulting in a 20-fold reduction in inhibitory activity. Some of
the sulfated tetrameric cyclitols with longer alkyl chain spacers
(compounds 7, 9, and 10) also showed weak inhibitory activity.
The more highly sulfated 6a was also a modest inhibitor unlike
the structurally similar but less sulfated 6. Similarly, the sul-
FIG. 4. Ability of a range of sulfated
linked cyclitols to inhibit the enzy-
matic activity of heparanase and ca-
thepsin G. Enzyme assays performed as
described under “Experimental Proce-
dures ” with data being presented as con-
centration (nanomolar) of each inhibitor
required to reduce enzymatic activity of
heparanase (A) or cathepsin G (B) by 50%
(IC50). The heparan sulfate mimetic, PI-
88, is included for comparison. IC50 val-
ues derived from pooled data from 8–10
determinations with vertical bars repre-
senting S.E.
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fated pentameric cyclitol (compound 14) was a relatively weak
inhibitor. In fact, compound 13 was the only other cyclitol with
an IC50 approaching that of compound 2. This result is partic-
ularly interesting, because it implies that the insertion of a
centrally placed, negatively charged, sulfate group in the pro-
pylene chain spacer converts this construct from an inactive to
an active compound, i.e. compare the IC50 of 13 with that of 3.
Inhibition of ECM-degrading Enzymes by Sulfated Cycli-
tols—The different sulfated cyclitols were assessed for their
ability to inhibit the enzymatic activity of a number of ECM-
degrading enzymes. PI-88 was originally developed as a
heparanase inhibitor, so it was of considerable interest to de-
termine the heparanase inhibitory activity of the 15 sulfated
cyclitols (Fig. 4A). It was found that only one of the synthetic
molecules, sulfated pentameric cyclitol (14), was as active as
PI-88, presumably because this entity presents a relatively
linear array of sulfated pseudo-sugars to the active site of the
enzyme. Although the other sulfated cyclitols were relatively
poor heparanase inhibitors, some structure-activity relation-
ship information could be gleaned from the data. For example,
relative to alkyl chain length, IC50 values followed a bell-
shaped curve with the 2- and 9-carbon spacers producing the
most active compounds and the sulfated tetracyclitol contain-
ing a 6-carbon spacer (6) being virtually inactive. It is notewor-
thy, however, that the more highly sulfated version of com-
pound 6 (i.e. 6a) possessed similar activity to compound 9. In
direct contrast to the situation observed with LpL, insertion of
a sulfate group in the propylene spacer had no effect on inhib-
itory activity. Interestingly, increasing the alkyl chain length
from 9 to 10 carbon atoms abolished inhibitory activity with the
more highly sulfated 10a also being a poor heparanase inhib-
itor. Finally, sulfated tetrameric cyclitols containing the more
rigid xylyl linkers were modest heparanase inhibitors.
In the case of the proteases elastase and cathepsin, as with
PI-88 (Table I), none of the 15 cyclitols proved capable of
inhibiting the enzymatic activity of elastase (data not shown).
In contrast, all of the sulfated cyclitols effectively inhibited
cathepsin G with most IC50 values only varying over a 2- to
3-fold range and resembling that of PI-88 (Fig. 4B). These data
suggest that the heparin/HS binding site of cathepsin G is
highly promiscuous and binds to short, highly negatively
charged, sugar sequences. One interesting feature of the ca-
thepsin G inhibition data, however, was that some of the com-
pounds only partially inhibited total enzymic activity. For ex-
ample, at high concentrations heparin and PI-88 reduced
cathepsin G activity by 90–95%, whereas compounds 6 and 10
only reduced the total activity of the enzyme by60 and80%,
respectively (Fig. 5A), despite PI-88, 6, and 10 having compa-
rable IC50 values (Fig. 4B). A similar situation was seen in the
LpL binding-inhibition experiments. Compounds 2 and 13
were the most active sulfated cyclitols in this system with the
former resembling PI-88 in terms of IC50 value (Fig. 3B). How-
ever, compound 2 consistently only blocked about 75% of LpL
binding compared with 90% by PI-88 (Fig. 5B). This effect was
even more extreme with compound 13, which only blocked LpL
binding by  60% at the highest concentration tested despite
PI-88, 2, and 13 blocking LpL binding to comparable levels
when used at very low concentrations (Fig. 5B).
DISCUSSION
Defining the structural motifs in HS that interact with dif-
ferent heparin/HS-binding proteins is a major challenge. The
usual approach has been to isolate HS fragments that bind to
particular proteins and then determine the structure of the
reactive fragments (32, 33). This is a difficult procedure as
there are often multiple binding motifs in HS of low abundance
and thus obtaining detailed structural information, particu-
larly of lengthy HS fragments, is a complex process. In an
attempt to overcome these difficulties we examined the ability
of a small family of well defined HS mimetics to interact with
10 functionally diverse heparin and/or HS-binding proteins. A
major advantage of this approach is that it is possible to rapidly
identify differences in binding specificity between different HS-
binding proteins, with a specific inhibitor of a particular pro-
tein-heparin/HS interaction being immediately available as a
potential therapeutic agent.
The HS mimetics used in this study consisted of cyclitol-
based pseudo-disaccharides that were “dimerized” using a
range of linker molecules. Alkyl chain linkers provided highly
hydrophobic and flexible spacers of variable chain length. In
contrast, the p-xylyl and m-xylyl linkers represent rigid and
non-polar spacers with varied orientations, whereas the addi-
tion of another cyclitol unit or a sulfated propylene chain as a
linker resulted in structures containing sulfated spacers. The
extent of sulfation of the individual cyclitol units was also
varied from three to five sulfate groups per unit. This level of
sulfation is much higher than would normally occur in heparin
or HS, but the potential exists in the future to synthesize
sulfated cyclitols with more limited and highly regio- and/or
stereo-specific sulfation patterns. Despite the high level of sul-
fation, 7 of the 10 proteins examined displayed a unique reac-
tivity pattern with the panel of sulfated cyclitols. The excep-
tions were HGF, eotaxin, and elastase, with none of the 15
sulfated cyclitols tested blocking the interaction of HGF and
eotaxin with heparin/HS or inhibiting elastase enzymatic ac-
tivity. In the case of eotaxin and elastase this result was not
surprising, because the sulfated oligosaccharide, PI-88, also
failed to interact with these proteins.
FIG. 5. Partial inhibition of cathepsin G enzymatic activity
and LpL binding to immobilized heparin by certain sulfated
linked cyclitols. A, cathepsin G data showing that compounds 6 and
10 only partially inhibit cathepsin G enzymatic activity, with heparin
and the heparan sulfate mimetic, PI-88, being included as controls. B,
LpL binding to immobilized heparin as measured by an optical biosen-
sor, with compounds 2 and 13 exhibiting partial inhibition of LpL
binding. The heparan sulfate mimetic, PI-88, is included for compari-
son. Data from the single experiment shown are representative of three
experiments conducted.
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Each of the HS-binding growth factors tested displayed
characteristic inhibition patterns with the most informative
compounds being the alkyl chain-linked tetrameric cyclitols.
Thus, in terms of blocking heparin/HS binding, compounds
with a spacer of 2–3 carbon atoms were the most inhibitory
for FGF-1 but were the least inhibitory for FGF-2 and
VEGF165, compounds with the longer alkyl chain linkers
being most effective against the latter two growth factors.
Despite these differences many of the sulfated cyclitols ex-
hibited substantial inhibitory activity against the three
growth factors, particularly FGF-1 and FGF-2. This finding is
consistent with earlier studies that suggest that, although
FGF-1 and FGF-2 bind HS sequences that vary in the posi-
tion and number of 6-O-sulfates, they bind a range of HS
sequences and there is substantial overlap in the sequences
they recognize (3, 18). In contrast, sulfated cyclitols with
short linkers (e.g. compounds 2, 3, and 13) were essentially
inactive against VEGF165 suggesting that this growth factor
interacts with long stretches of negatively charged residues
in HS. Earlier studies actually support this interpretation,
because VEGF165, the most abundant isoform of VEGF, is
most effectively inhibited from binding to VEGF receptors by
lengthy heparin fragments composed of 16–18 sugar units
(34). On the other hand, the failure of any of the sulfated
cyclitols to block the HGF-heparin interaction is surprising,
because HGF is known to bind to relatively short HS se-
quences (35). Perhaps HGF is the one example in this study
where the highly sulfated nature of the cyclitol derivatives
interfered with their ability to interact with the growth
factor.
Much more selective inhibition patterns were observed with
IL-8 and LpL. IL-8, a member of the CXC-chemokine family,
exists as a homodimer, and it has been suggested that the
molecule interacts with HS fragments containing two highly
sulfated hexasaccharides joined by a non- or under-sulfated
dodecasaccharide linker (36). The results obtained with the
sulfated cyclitols support this interpretation, because inhibi-
tory activity was highly dependent on the chain length of the
alkyl linkers, i.e. a linker of 7 carbon atoms was essential.
Presumably, linker length is crucial to allow the linked sulfated
pseudo-disaccharides to interact with the HS-binding site of
each subunit of the IL-8 dimer. In contrast, none of the sulfated
compounds tested, including PI-88, could block eotaxin binding
to heparin. Eotaxin also exists as a homodimer (37), so it is
likely that the appropriately spaced sulfated motifs were not
present in the limited family of sulfated molecules tested. Sul-
fated cyclitol linker length was also critical for LpL binding
inhibition, although in this case a very short spacer was re-
quired for optimal inhibitory activity. Enzymatically active
LpL exists as a homodimer that has a high affinity for heparin
and HS and interacts most strongly with heparin octa- to
decasaccharides (38). Our results suggest that the spatial ar-
rangement of the sulfated regions in HS are critical, perhaps to
adequately bridge the LpL dimers, as is the case with the
chemokines.
Finally, certain sulfated cyclitols were also found to be potent
enzyme inhibitors, in some cases achieving the potency of PI-
88. The general conclusion from the heparanase inhibition
studies was that HS mimetics that resemble a sulfated pen-
tasaccharide were the most effective inhibitors. Compounds
that contained non-sulfated hydrophobic linkers were poor in-
hibitors. In contrast, all of the sulfated cyclitols were quite
potent cathepsin G inhibitors, suggesting that this enzyme
reacts with a wide range of short polyanions. One intriguing
feature of the cathepsin G data, however, was the observation
that only a subpopulation of enzyme molecules were inacti-
vated by the sulfated cyclitols, the extent of partial inhibition
varying from compound to compound. Similar partial inhibi-
tion of heparin binding was also observed with LpL and com-
pound 13. These data suggest that both cathepsin G and LpL
exist in states that exhibit differential HS-binding properties.
The functional relevance of this phenomenon may be that it
prevents HS fragments released from the ECM at sites of
inflammation and tissue repair from totally displacing LpL
from the matrix or totally inactivating ECM-degrading en-
zymes such as cathepsin G.
Collectively this study has highlighted the power of using a
simple panel of HS mimetics to delineate differences in the HS
binding specificity of proteins. Clearly the spatial separation of
anionic groups within the HS mimetics plays a critical role in
determining the specificity of interaction. This point is most
clearly evident with two of the sulfated tetrameric cyclitols,
compounds 2 and 8, which only differ by the length of their
alkyl chain spacer, i.e. 2 and 8 carbon atoms, respectively.
Despite this similarity in structure compound 2 is a modest
inhibitor of FGF-2 and a very effective inhibitor of FGF-1 and
LpL binding to heparin/HS but is inactive against VEGF and
IL-8, whereas compound 8 possesses exactly the opposite prop-
erties, being a modest inhibitor of FGF-1 binding, and a strong
inhibitor of FGF-2, VEGF, and IL-8 binding. Such data also
indicate that an HS mimetic approach provides a means of
rapidly identifying compounds that may have therapeutic
value by specifically blocking the action of certain HS-binding
proteins in pathological situations.
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